DAVID NATAN - 26 Feb 2025 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role
Director
Signature
/s/ David Natan
Issuer symbol
CYCC
Transactions as of
26 Feb 2025
Net transactions value
$0
Form type
4
Filing time
28 Feb 2025, 16:48:59 UTC
Previous filing
07 Jan 2025
Next filing
14 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYCC Non-Qualified Stock Option (Right to Buy) Award $0 +700,000 $0.000000 700,000 26 Feb 2025 Common Stock 700,000 $0.3300 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 26, 2025 (the "Grant Date"), the Reporting Person was granted 700,000 Non-Qualified Stock Options to purchased shares of common stock (the "Common Stock") of Cyclacel Pharmaceuticals, Inc. (the "Company") in consideration of his services as a director of the Company. The option grant became exercisable on the Grant Date.
F2 Includes shares of Common Stock previously reported in Table I of the Reporting Person's Form 4 filed on January 7, 2025, which were not issued by the Company and are being replaced with the option grant reported in this Form 4.